Continuation of bevacizumab and addition of hormone therapy following weekly paclitaxel therapy in HER2-negative metastatic breast cancer

BACKGROUND: Bevacizumab plus taxane chemotherapy improves progression-free survival (PFS) versus taxane monotherapy in the first-line treatment of HER2-negative metastatic breast cancer (MBC) and appears promising in the second-line setting. This retrospective analysis evaluated the efficacy and saf...

Full description

Saved in:
Bibliographic Details
Published in:Onco Targets Ther
Main Authors: Redondo, Andrés, Martínez, Virginia, Zamora, Pilar, Castelo, Beatriz, Pinto, Alvaro, Cruz, Patricia, Higuera, Oliver, Mendiola, Marta, Hardisson, David, Espinosa, Enrique
Format: Artigo
Language:Inglês
Published: Dove Medical Press 2014
Subjects:
Original Research
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC4251573/
https://ncbi.nlm.nih.gov/pubmed/25473300
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/OTT.S70654
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items